BIOTECH COMPANY DEVELOPING MICROARRAY PATCH PLATFORM FOR THERAPEUTICS WILL ESTABLISH NEW HEADQUARTERS AND MANUFACTURING FACILITY IN BOSTON

BOSTON, March 26, 2026 — Terrestrial Bio, Inc., formerly Vaxess Technologies, Inc., today announced $50 million in Series C funding. RA Capital led the round, with support from Engine Ventures, GHIC, and SiteGround. Additionally, Terrestrial is announcing a rebrand from Vaxess Technologies to reflect the company’s strategic focus on transforming the delivery and accessibility of therapies, starting with GLP-1. The company has also signed a lease in Boston to expand its manufacturing capabilities and establish its new headquarters as it prepares for clinical trials and commercialization of its lead GLP-1 program.

“In recent years, it became clear that our company name should more clearly reflect our focus on therapies and patient-centered delivery,” said Rachel Sha, CEO of Terrestrial. “Healthcare has become increasingly consumerized, with patient experience and access playing a growing role in how people choose therapies. The Terrestrial name reflects the company’s ambition to make therapeutics more patient-friendly for people around the world, while also pointing to the skin or surface-based nature of our proprietary microarray patch technology.”

At the core of Terrestrial’s vision is a future where therapies are much more patient-friendly in how they’re purchased, administered, and stored. By removing sharps and eliminating the need for refrigeration, Terrestrial’s microarray patch (MAP) platform enables therapeutics to be self-administered in the comfort and convenience of a patient’s own home or when they’re traveling. According to the company’s recent GLP-1 human factors study, nearly all participants expressed a preference for the patch applicator over traditional injection devices.

With its new funding, Terrestrial has signed a lease with King Street Properties for a new manufacturing facility at Allston Labworks. The facility will span more than 40,000 square feet, supporting automated, scaled production of the company’s microarray patches to support late-stage clinical development and early commercial entry. As Terrestrial builds out its new manufacturing facility beginning in 2026, it will incorporate leading automation, robotics, computer vision, and quality control processes.

About Terrestrial Bio, Inc.

Terrestrial is transforming the delivery of next-generation therapies, starting with GLP-1.

Terrestrial’s proprietary microarray patch (MAP) and applicator platform consists of a patch resembling an adhesive bandage, which is applied with a preloaded applicator and removed after a few minutes. Once applied, each patch delivers bioactive tips into the skin, which dissolve quickly into the body, rapidly releasing their therapeutic payload. Designed for self-administration, the temperature-stable MAP platform enables precise, controlled delivery of a wide range of therapeutics without medical sharps or refrigeration.

Terrestrial has generated strong clinical and in-vivo proof of concept across multiple molecules. For more information, visit www.terrestrialbio.com